Clinical Trial Update: Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating temozolomide with or without capecitabine in advanced pancreatic neuroendocrine tumors, including subtypes such as gastrinoma, glucagon…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrinoma
• Glucagonoma
• Insulinoma
• Islet Cell Carcinoma
• Pancreatic Neuroendocrine Tumor
• Pancreatic Polypeptide Tumor
• Somatostatinoma

Drugs mentioned

• Capecitabine (capecitabine)
• Temozolomide (Temozolomide)

Snippet

Sponsor: ECOG-ACRIN Cancer Research Group | Conditions: Gastrinoma, Glucagonoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-10-19